cheers @Tiglah
Call centres are required in all the contacts/MOUs, including Boletong & B.Silverlake & FCL
Recurring income from Prizma monitoring subscritpions is U$3 (basic) to $10 to $30 (premium) a month
@more4less, can you confirm figures?
Boletong hosptials' patients are likely to subscribe at what price?
500,000
x $U$36/year = U$18M/year
x U$120/yr = U$60M/yr
600,000 units to 1 million units( if full production/year is sold)
NEWS
https://gmedinnovations.com/asx-announcements/Here are some (not all) FA related asx anns:
20/01/20
Taiwan FDA Approval Granted for Prizma17/01/20, Nmpa
Prizma Clinical Trials Completed for China Approval Process22/10/19
Response to ASX Query ( Summary of Nmpa situations, MOUs, Management contacts with MOU partners etc)12/12/19
G Medical Continues Rapid Growth in USA4/11/19
G Medical Secures $30 million Funding Facility30/10/19
(Capacity, 1 million Prizma units/year, X numbers of GMPAtch)
CE, FDA and CFDA Approval - Guangzhou Production Facility8/8/18
Proposed IPO of China Subsidiary in Hong Kong11/10/17
Binding MOU for Distribution in India and Taiwan2/10/18
Underwriter engaged to manage dual-listing on Nasdaq22/5/17, 70/30 Jv
G Medical Signs China Joint Venture AgreementBoletong:
27/7/17,
http://www.sdboletong.com/index.php?s=/List/index/cid/22.html
U$65m, year 1, plus 5 years monitor/support service
G Medical Signs Binding MOU for China DistributionJuicy Bits:
http://www.sdboletong.com/index.php?s=/List/index/cid/22.html
Partners incl 3 regional hospitals in china
9 million
p7
Response to ASX Query.
Pg7
1.2.GMV understands that Boletong holds a government contract for the provision of monitoring services topatientswithina regional population of circa 9million individuals, under which it receives reimbursement for each patient monitored;
1.3.GMVunderstandsthatBoletonghassignificantinvestmentbackingfromaTier1Chinesepharmaceutical company as well as having sufficient revenues in its own capacity to satisfy the financial requirements under the Boletong Agreement;
1.4.GMVandBoletongintendto establish a joint venture partnership pursuanttowhichBoletonghasagreedtoestablisha
50 to 60(persons)doctors and nurses centre for the provision of healthca reservices; and
1.5.recent communications between Dr Geva with the CEO of Boletong, who has personally confirmed that theBoletongAgreementremainsunchangedandthatBoletongawaitsnotificationfromHMVinrespect to the grant of NMPA approval in respect of the Prizma device.
DYOR
